TL;DR
This study investigated whether fimasartan, an angiotensin II receptor blocker, could reduce carotid atherosclerotic plaque inflammation more effectively than amlodipine, a calcium channel blocker, in patients with acute coronary syndrome (ACS). The findings indicate that both drugs similarly reduced plaque inflammation, suggesting comparable effectiveness in this context.
What Problem Does This Paper Address?
Atherosclerosis, the buildup of plaque in arteries, is a major contributor to cardiovascular disease. Inflammation within these plaques is a key driver of their progression and instability, increasing the risk of heart attacks and strokes. The renin-angiotensin system (RAS) is known to play a role in promoting this inflammation. Angiotensin II receptor blockers (ARBs) like fimasartan are designed to inhibit this system. Calcium channel blockers (CCBs) like amlodipine are also commonly used for cardiovascular conditions. While both drug classes can lower blood pressure, their comparative effects on atherosclerotic plaque inflammation, independent of blood pressure reduction, were not well understood. This study aimed to fill that knowledge gap by directly comparing fimasartan and amlodipine's impact on carotid plaque inflammation.
Methods
The study employed a prospective, open-label, randomized, single-center design. Fifty patients with acute coronary syndrome (ACS) and evidence of carotid artery disease were randomly assigned to receive either fimasartan (60 mg/day) or amlodipine (5 mg/day) for six months. The primary method for assessing plaque inflammation was 18F-fluorodeoxyglucose (18FDG) positron emission tomography/computed tomography (PET/CT) imaging. This technique visualizes areas of increased metabolic activity, which in atherosclerotic plaques is indicative of macrophage infiltration and inflammation. Specifically, the researchers measured the target-to-background ratio (TBR) in the most diseased segment (MDS TBR) of the index carotid artery. This measurement was taken at baseline and again at the 6-month follow-up. Other assessments included blood pressure, lipid profiles, and high-sensitivity C-reactive protein (Hs-CRP) levels.
Datasets
Not discussed in the paper. The study involved patient data collected through clinical assessments and imaging.
Key Insights and Ideas
- Inflammation as a Therapeutic Target: The study reinforces the idea that atherosclerotic plaque inflammation is a viable target for therapeutic intervention, with imaging techniques like 18FDG PET/CT proving useful for monitoring changes.
- RAS Blockers Beyond BP Control: While ARBs are known to inhibit the RAS, their specific anti-inflammatory effects on plaques, independent of blood pressure reduction, are an area of ongoing research. This study contributes to understanding these pleiotropic effects.
- Potential for Dilution of Effects: The authors suggest that the intensive lipid-lowering therapy (statins) used by all patients in the study might have diluted any potential superior anti-inflammatory effects of fimasartan, leading to similar outcomes with amlodipine.
Key Results
- Both fimasartan and amlodipine groups showed a significant decrease in the most diseased segment (MDS) TBR of the index carotid artery after 6 months (P < 0.05).
- Crucially, the percent change in index vessel MDS TBR (the primary endpoint) was not significantly different between the fimasartan group (-9.33 ± 14.2%) and the amlodipine group (-7.73 ± 19.1%) (P = 0.900).
- Whole vessel TBR of the index carotid artery significantly decreased in the fimasartan group (P = 0.019) but not in the amlodipine group (P = 0.152). However, the percent change in whole vessel TBR was not significantly different between the groups.
- Similar findings were observed for changes in TBR in the aorta.
- Both groups experienced similar improvements in total cholesterol, LDL cholesterol, and blood pressure. Triglyceride and HDL cholesterol levels did not significantly change in either group.
- Hs-CRP levels significantly decreased in the fimasartan group but not in the amlodipine group.
Limitations and Future Work
The authors acknowledge several limitations:
- Small Sample Size: The study was limited by the number of patients, which may have reduced its power to detect subtle differences in arterial inflammation.
- Open-Label, Single-Center Design: This design is subject to inherent limitations, although the use of blinded 18FDG PET/CT evaluations aimed to mitigate this.
Future work could involve larger, multi-center trials with a higher statistical power to confirm these findings and explore the specific mechanisms by which these drugs impact plaque inflammation, especially in the context of aggressive lipid-lowering therapy. Further investigation into the role of RAS blockers beyond blood pressure reduction in cardiovascular disease remains an important area.
Summary updated